Products for Research Use Only

Dexrazoxane (hydrochloride)

CAT: 0804-HY-76201-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-76201-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a heart protectant that can help preserve ovarian function and fertility. Dexrazoxane hydrochloride has antioxidant and anti-inflammatory properties, can cross the blood-brain barrier, improves motor function disorders, and offers neuroprotective effects, making it useful in the study of neurodegenerative diseases[1][2][3][4].
CAS Number
149003-01-0
Product Name Alternative
ICRF-187 (hydrochloride) ; ADR-529 (hydrochloride) ; NSC-169780 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Dexrazoxane-Hydrochloride.html
Purity
99.83
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic)
Smiles
C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O.[H]Cl.[H]Cl
Molecular Formula
C11H18Cl2N4O4
Molecular Weight
341.19
Precautions
H302, H315, H319, H335
References & Citations
[1]Jenna Kropp, et al. Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice. PLoS One. 2015 Nov 6;10 (11) :e0142588. |[2]A R Imondiv, et al. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res. 1996 Sep 15;56 (18) :4200-4.|[3]Meng Mei, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1:160:107758.|[4]Shiwei Deng, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172 (9) :2246-57.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Br J Pharmacol. 2025 Jun;182 (11) :2409-2425.|Environ Toxicol Pharmacol. 2023 Oct:103:104261.|Nat Med. 2016 May;22 (5) :547-56. |Phytomedicine. 2025 Nov:147:157220.|Adv Sci (Weinh) . 2023 May;10 (15) :e2206007.|Biochem Biophys Res Commun. 2025 Sep 8:778:152417.|Biochem Pharmacol. 2024 Jun:224:116247.|Biomed Pharmacother. 2022 Sep:153:113280.|Cardiovasc Toxicol. 2024 Aug;24 (8) :818-835.|Eur J Med Chem. 2024 Nov 26:283:117108.|Free Radic Biol Med. 2020 Nov 20;160:303-318.|Free Radic Biol Med. 2024 Dec 9:227:296-311.|J Cell Mol Med. 2025 Jun;29 (11) :e70641.|J Ethnopharmacol. 2025 Oct 14:120751.|Mol Med Rep. 2024 May;29 (5) :84.|Nano Res. 2023 Apr 18.|Phytomedicine. 2023 Aug:117:154922.|Phytomedicine. 2025 Oct 3:148:157357.